You are here

P&T November 2012


As value-based reimbursement and accountable-care models drive us into an era of cost-containment and care-management strategies, the P&T committee must reinvent itself.
Health Care & Law
An Improvement Over HMOs?

The ACO model is considered an important achievement of health care reform legislation. However, ACOs might not be able to deliver on their promises in part because of the slowly recovering economy. It is also not clear how much money will be saved, and not all hospitals plan to participate.

Part 3: Regulatory and Safety Challenges

Before the FDA can set up safety guidelines for nanomedicines, it needs to establish valid testing criteria. The goal is to strike a balance between underregulation (which can lead to questionable approvals) and overregulation (which can inhibit innovation).

Perspectives in the United States
Twenty percent to 30% of CML patients are not being treated according to clinical practice guidelines. The authors review the most recent guidelines published by the National Comprehensive Cancer Network and the European LeukemiaNet.


Medication Errors
Basal opioid infusions may raise the risk of respiratory depression when given with patient-controlled analgesia.
Prescription: Washington

A new Medicare “G” code for transitional care may help to reduce the number of hospital readmissions.

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Bosutinib (Bosulif) tablets for chronic myelogenous leukemia; linaclotide (Linzess) for irritable bowel syndrome/constipation and chronic idiopathic constipation; and regorefenib (Stivarga) tablets for metastatic colorectal cancer